Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 12, 2004. The report details a share repurchase transaction executed on May 10, 2004, and updates regarding directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 750,000 Ordinary Shares of 25 pence each.
- Purchase Price: 1,184.41 pence per share.
- Treasury Holdings: 10,940,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,922,368,113 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 750,000 shares. Additionally, the GlaxoSmithKline US Retirement Savings Plan saw an increase in its holdings of Ordinary Share ADRs from 18,665,762 to 18,727,936 due to fund movements on May 7, 2004, at an average price of $43.06.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 750,000 share repurchase against the stated price of 1,184.41 pence per share.
- Confirm the updated total share count of 5,922,368,113 shares in issue.
- Note that Directors Dr. J.P. Garnier and Dr. T. Yamada have potential indirect interests in the US Retirement Savings Plan, which holds over 18.7 million ADRs.
- Recognize that this filing does not contain quarterly or annual financial performance data.